{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:14:45Z","timestamp":1784139285509,"version":"3.55.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1097\/01.coc.0000135570.37287.7f","type":"journal-article","created":{"date-parts":[[2004,9,30]],"date-time":"2004-09-30T08:08:57Z","timestamp":1096531737000},"page":"522-528","source":"Crossref","is-referenced-by-count":44,"title":["The Influence of Intravesical Therapy on Progression of Superficial Transitional Cell Carcinoma of the Bladder"],"prefix":"10.1097","volume":"27","author":[{"given":"Michael","family":"Huncharek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Kupelnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","article-title":"Cancer statistics, 2001.","volume":"51","author":"Greenlee","year":"2001","journal-title":"CA Cancer J Clin"},{"key":"R2-19-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14656566.3.6.671","article-title":"Pharmacotherapy of bladder cancer-practice and prospects.","volume":"3","author":"Nawrocki","year":"2002","journal-title":"Exp Opin Pharmacother"},{"key":"R3-19-20210128","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0895-4356(99)00203-6","article-title":"Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3,703 patients from 11 randomized trials.","volume":"53","author":"Huncharek","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"R4-19-20210128","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"R5-19-20210128","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/01.COC.0000026911.98171.C6","article-title":"Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: a meta-analytic re-evaluation.","volume":"26","author":"Huncharek","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"R6-19-20210128","article-title":"The Handbook of Research Synthesis.","author":"Cooper","year":"1994"},{"key":"R7-19-20210128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta-blockade during and after myocardial infarction: an overview of the randomized trials.","volume":"7","author":"Yusuf","year":"1985","journal-title":"Prog Cardiovasc Dis"},{"key":"R8-19-20210128","article-title":"Meta-analysis, Decision Analysis and Cost-Effectiveness Analysis. Methods for Quantitative Synthesis in Medicine, 2nd ed.","author":"Petitti","year":"2000"},{"key":"R9-19-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-5347(17)52736-6","article-title":"Experience with Bacillus Calmette-Guerin in patients with superficial bladder carcinoma.","volume":"128","author":"Brosman","year":"1982","journal-title":"J Urol"},{"issue":"suppl","key":"R10-19-20210128","first-page":"20","article-title":"BCG (RIVM) versus mitomycin C intravesical therapy in superficial bladder cancer.","volume":"30","author":"Debruyne","year":"1980","journal-title":"Urology"},{"key":"R11-19-20210128","first-page":"435","article-title":"BCG (RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer.","author":"Debruyne","year":"1989","journal-title":"Therapeutic Progress in Urological Cancers"},{"key":"R12-19-20210128","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","article-title":"A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus Bacillus Calmette-Guerin.","volume":"156","author":"Krege","year":"1996","journal-title":"J Urol"},{"key":"R13-19-20210128","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-5347(01)65853-1","article-title":"A randomized prospective study comparing long-term intravesical instillations of mitomycin C and Bacillus Calmette-Guerin in patients with superficial bladder carcinoma.","volume":"156","author":"Lundholm","year":"1996","journal-title":"J Urol"},{"key":"R14-19-20210128","first-page":"263","article-title":"Adriamycin versus BCG in superficial bladder cancer. A Southwest Oncology Group Study.","volume":"6","author":"Lamm","year":"1989","journal-title":"EORTC Genitourinary Group Monograph"},{"key":"R15-19-20210128","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000281212","article-title":"A trial of Bacillus Calmette-Guerin versus adriamycin in superficial bladder cancer. A Southwest Oncology Group Study.","volume":"41","author":"Mori","year":"1986","journal-title":"Urol Int"},{"key":"R17-19-20210128","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0959-8049(93)90102-L","article-title":"A randomized prospective study comparing intravesical instillations of mitomycin C, BCG-TICE and BCG-RIVM in pTa-pT1 tumors and primary carcinoma in situ of the urinary bladder.","volume":"29A","author":"Witjes","year":"1993","journal-title":"Eur J Cancer"},{"key":"R18-19-20210128","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guerin for transitional cell carcinoma of the bladder.","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"key":"R19-19-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of Bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. A Southwest Oncology Group Study.","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol"},{"key":"R20-19-20210128","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma.","volume":"161","author":"Malmstrom","year":"1999","journal-title":"J Urol"},{"key":"R21-19-20210128","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(17)40002-4","article-title":"Bacillus Calmette-Guerin versus doxorubicin versus thiotepa. A randomized prospective study in 202 patients with superficial bladder cancer.","volume":"143","author":"Martinez-Pineiro","year":"1990","journal-title":"J Urol"},{"key":"R22-19-20210128","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF02550957","article-title":"BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumors: results of a prospective randomized study using modified treatment schemes.","volume":"28","author":"Melekos","year":"1996","journal-title":"Int Urol Nephrol"},{"key":"R23-19-20210128","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000227574","article-title":"Intravesical Bacillus Calmette-Guerin versus epirubicin in the prophylaxis of recurrent and\/or multiple superficial bladder tumors.","volume":"53","author":"Melekos","year":"1996","journal-title":"Oncology"},{"key":"R24-19-20210128","first-page":"19","article-title":"Intravesical chemotherapy (mitomycin C) versus immunotherapy (BCG) in superficial bladder cancer.","volume":"20","author":"Rintala","year":"1991","journal-title":"Eur Oncol"},{"key":"R25-19-20210128","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0022-5347(01)67606-7","article-title":"A randomized study of intravesical mitomycin C, BCG-Tice and BCG-RIVM treatment of pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder.","volume":"153","author":"Vegt","year":"1995","journal-title":"J Urol"},{"key":"R26-19-20210128","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0090-4295(98)00212-X","article-title":"Long-term follow up of an EORTC randomized prospective trial comparing intravesical BCG-RIVM and mitomycin C in superficial bladder cancer.","volume":"52","author":"Witjes","year":"1998","journal-title":"Urology"},{"key":"R27-19-20210128","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","article-title":"Intravesical instillation of epirubicin, BCG and BCG plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: A European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III Trial.","volume":"166","author":"van der Meijden","year":"2001","journal-title":"J Urol"},{"key":"R28-19-20210128","first-page":"280","article-title":"Intravesical therapy for superficial bladder cancer.","volume":"18","author":"Malkowicz","year":"2000","journal-title":"Semin Urol Oncol"},{"key":"R29-19-20210128","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0022-5347(01)67427-5","article-title":"Apparent failure of current intravesical chemotherapy prophylaxis to influence the long term course of superficial transitional cell carcinoma of the bladder.","volume":"153","author":"Lamm","year":"1995","journal-title":"J Urol"},{"key":"R30-19-20210128","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00000421-200410000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T04:24:34Z","timestamp":1618028674000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-200410000-00019"}},"subtitle":["A Metaanalytic Comparison of Chemotherapy versus Bacilli Calmette-Guerin Immunotherapy"],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1097\/01.coc.0000135570.37287.7f","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}